Casirivimab clinical trials
Counted the way a researcher would: Casirivimab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses casirivimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 12 Nov 2021 · Ronapreve · EMEA/H/C/005814 (EMA; in a combination; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Regeneron Pharmaceuticals (3) · Sohail Rao (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses casirivimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19TerminatedPhase 3Regeneron PharmaceuticalsNCT04425629Written as casirivimab+imdevimab combination therapy
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19CompletedPhase 1/2Regeneron PharmaceuticalsNCT04426695Written as REGN10933+REGN10987 combination therapy
- COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 InfectionCompletedPhase 2Regeneron PharmaceuticalsNCT04666441Written as REGN10933+REGN10987 combination therapy
- Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized SettingStatus unknownPhase 2Sohail RaoNCT04840459Written as CASIRIVIMAB
Codes
What other systems call casirivimab · ClinicalTrials.gg INT001452
- MeSH (NLM) C000711487casirivimabOne source NLM
- UNII (FDA) J0FI6WE1QNCASIRIVIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2465242Confirmed FDA, Wikidata
- Wikidata Q99329744casirivimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C177087CasirivimabOne source FDA
- DrugBank DB15941One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711487 | casirivimab | One source NLM |
| UNII (FDA) | J0FI6WE1QN | CASIRIVIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2465242 | — | Confirmed FDA, Wikidata |
| Wikidata | Q99329744 | casirivimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C177087 | Casirivimab | One source FDA |
| DrugBank | DB15941 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.